uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience. neurologi.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience. neurologi.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience. neurologi.
2008 (English)In: European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, E-ISSN 1619-7089, Vol. 35, no 1, 65-71 p.Article in journal (Refereed) Published
Abstract [en]

PURPOSE:

The management of adult patients with grade 2 gliomas remains a challenge for the clinical neuro-oncologist. Several clinical prognostic factors appear to be as important as treatment factors in determining outcome. From the European Organisation for Research and Treatment of Cancer (EORTC) trials 22844 and 22845, a prognostic scoring system has been proposed based on the presence of unfavourable prognostic factors. The aim of the present study was to assess the additional prognostic value of (11)C-methionine (MET) measured by positron emission tomography (PET) in the setting of the EORTC prognostic scoring system.

METHODS:

In this retrospective review, 129 patients with supratentorial grade 2 gliomas were subjected to a PET study as part of the pre-treatment tumour investigation. One hundred and three cases were classified as low-risk patients (0-2 unfavourable factors) and 26 cases as high-risk patients (3-5 unfavourable factors) according to the EORTC criteria. MET PET was evaluated as an extra prognostic factor in both groups.

RESULTS:

In the high-risk group, patients with high MET uptake had a worse outcome than patients with low MET uptake. A similar trend was found for the low-risk group in patients with oligodendrocytic tumours.

CONCLUSIONS:

Our findings further strengthen the role of MET PET as an important prognostic tool in the management of this group of patients.

Place, publisher, year, edition, pages
2008. Vol. 35, no 1, 65-71 p.
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-12545DOI: 10.1007/s00259-007-0531-1PubMedID: 17710394OAI: oai:DiVA.org:uu-12545DiVA: diva2:40314
Available from: 2008-01-04 Created: 2008-01-04 Last updated: 2017-12-11Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedhttp://www.neuro.uu.se

Authority records BETA

Smits, AnjaWesterberg, Elisabet

Search in DiVA

By author/editor
Smits, AnjaWesterberg, Elisabet
By organisation
Department of Neuroscience
In the same journal
European Journal of Nuclear Medicine and Molecular Imaging
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 631 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf